WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H526593
CAS#: 1675201-90-7
Description: BMS-8 is a novel inhibitor of the PD-1/PD-L1 interaction by inducing PD-L1 dimerization through PD-1 interacting surface, binding at a hydrophobic cavity formed upon PD-L1 dimerization.
Hodoodo Cat#: H526593
Name: BMS-8
CAS#: 1675201-90-7
Chemical Formula: C27H28BrNO3
Exact Mass: 493.13
Molecular Weight: 494.429
Elemental Analysis: C, 65.59; H, 5.71; Br, 16.16; N, 2.83; O, 9.71
Synonym: BMS8; BMS 8; BMS-8
IUPAC/Chemical Name: 1-[3-Bromo-4-(2-methyl-biphenyl-3-ylmethoxy)-benzyl]-piperidine-2-carboxylic acid
InChi Key: QRXBPPWUGITQLE-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H28BrNO3/c1-19-22(10-7-11-23(19)21-8-3-2-4-9-21)18-32-26-14-13-20(16-24(26)28)17-29-15-6-5-12-25(29)27(30)31/h2-4,7-11,13-14,16,25H,5-6,12,15,17-18H2,1H3,(H,30,31)
SMILES Code: O=C(C1N(CC2=CC=C(OCC3=C(C)C(C4=CC=CC=C4)=CC=C3)C(Br)=C2)CCCC1)O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 494.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, Monestier S, Mallet S, Richard MA, Régis JM, Grob JJ. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017 Oct;84:44-54. doi: 10.1016/j.ejca.2017.07.017. Epub 2017 Aug 4. PubMed PMID: 28783540.
2: Vahl TP, Gasior P, Gongora CA, Ramzipoor K, Lee C, Cheng Y, McGregor J, Shibuya M, Estrada EA, Conditt GB, Kaluza GL, Granada JF. Four-year polymer biocompatibility and vascular healing profile of a novel ultrahigh molecular weight amorphous PLLA bioresorbable vascular scaffold: an OCT study in healthy porcine coronary arteries. EuroIntervention. 2016 Dec 20;12(12):1510-1518. doi: 10.4244/EIJ-D-16-00308. PubMed PMID: 27998842.
3: Zhang BC, Wang C, Li WH, Li DY. Clinical outcome of drug-eluting versus bare-metal stents in patients with calcified coronary lesions: a meta-analysis. Intern Med J. 2015 Feb;45(2):203-11. doi: 10.1111/imj.12622. Review. PubMed PMID: 25370798.
4: Barennes H, Empis G, Quang TD, Sengkhamyong K, Phasavath P, Harimanana A, Sambany EM, Koffi PN. Breast-milk substitutes: a new old-threat for breastfeeding policy in developing countries. A case study in a traditionally high breastfeeding country. PLoS One. 2012;7(2):e30634. doi: 10.1371/journal.pone.0030634. Epub 2012 Feb 9. PubMed PMID: 22347392; PubMed Central PMCID: PMC3276495.
5: Kyono H, Guagliumi G, Sirbu V, Rosenthal N, Tahara S, Musumeci G, Trivisonno A, Bezerra HG, Costa MA. Optical coherence tomography (OCT) strut-level analysis of drug-eluting stents (DES) in human coronary bifurcations. EuroIntervention. 2010 May;6(1):69-77. doi: 10.4244/. PubMed PMID: 20542800.
6: De Felice F, Fiorilli R, Parma A, Nazzaro M, Musto C, Sbraga F, Caferri G, Violini R. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents. JACC Cardiovasc Interv. 2009 Dec;2(12):1260-5. doi: 10.1016/j.jcin.2009.09.013. PubMed PMID: 20129553.
7: Granada JF, Alviar CL, Wallace-Bradley D, Osteen M, Dave B, Tellez A, Win HK, Kleiman NS, Kaluza GL, Lev EI. Patterns of activation and deposition of platelets exposed to the polymeric surface of the paclitaxel eluting stent. J Thromb Thrombolysis. 2010 Jan;29(1):60-9. doi: 10.1007/s11239-009-0348-9. PubMed PMID: 19466381.
8: Nakamura K, Funabashi N, Uehara M, Suzuki K, Terao M, Okubo K, Mita Y, Maeda F, Komuro I. Impairment factors for evaluating the patency of drug-eluting stents and bare metal stents in coronary arteries by 64-slice computed tomography versus conventional coronary angiography. Int J Cardiol. 2008 Nov 28;130(3):349-56. doi: 10.1016/j.ijcard.2007.08.104. Epub 2008 Jan 3. PubMed PMID: 18180050.
9: Kupferwasser LI, Amorn AM, Kapoor N, Lee MS, Kar S, Cercek B, Dohad S, Mirocha J, Forrester JS, Shah PK, Makkar RR. Comparison of drug-eluting stents with bare metal stents in unselected patients with acute myocardial infarction. Catheter Cardiovasc Interv. 2007 Jul 1;70(1):1-8. PubMed PMID: 17580366.
10: Novales-Li P. Characterization of immunoglobulin M antibodies raised by in vitro immunization specific to soluble human caudate nucleus and cerebrospinal fluid acetylcholinesterase. Biochem Biophys Res Commun. 1994 Sep 15;203(2):1076-82. PubMed PMID: 8093024.
